Høhloch, Karin

[["dc.bibliographiccitation.firstpage","538"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.bibliographiccitation.lastpage","544"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Trümper, L."],["dc.contributor.author","Zwick, C."],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Hohloch, K."],["dc.contributor.author","Schmits, R."],["dc.contributor.author","Mohren, M."],["dc.contributor.author","Liersch, R."],["dc.contributor.author","Bentz, M."],["dc.contributor.author","Graeven, U."],["dc.contributor.author","Wruck, U."],["dc.contributor.author","Hoffmann, M."],["dc.contributor.author","Metzner, B."],["dc.contributor.author","Hasenclever, D."],["dc.contributor.author","Loeffler, M."],["dc.contributor.author","Pfreundschuh, M."],["dc.date.accessioned","2019-07-09T11:53:01Z"],["dc.date.available","2019-07-09T11:53:01Z"],["dc.date.issued","2007"],["dc.description.abstract","Background: To determine the maximum tolerated dose of a bi- and tri-weekly combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone plus etoposide (CHOEP) regimen without stem-cell support. Patients and methods: Randomized phase I/II multicenter four-level (cyclophosphamide: 1000–1200–1400–1600 mg/m2; doxorubicin: 55–60–65–70 mg/m2; etoposide: 375–450–525–600 mg/m2) dose escalation study with CHOEP-14 and CHOEP-21 in young patients (18–60 years) with newly diagnosed aggressive non-Hodgkin’s lymphoma. Dose-limiting toxicity was defined as thrombocytopenia <80 000/mm3 and leukocytopenia <2500/mm3 on days 16 (CHOEP-14) and 23 (CHOEP-21) or prolonged (>4 days) leukocytopenia (<1000/mm3) or thrombocytopenia (<20 000/mm3). Results: One hundred and thirty-nine patients (high-CHOEP-14: 47, high-CHOEP-21: 92) were randomly allocated to the study. Maximal tolerated dose was level 2 for CHOEP-14 and level 4 for CHOEP-21. With a less favorable profile of patients in CHOEP-14, 4-year event-free survival was 47.9% after high-CHOEP-14 and 66.2% after high-CHOEP- 21, 4-year overall survival 62.1% after high-CHOEP-14 and 73.4% after high-CHOEP-21, respectively. Conclusion: Significant dose escalations of CHOEP are possible with granulocyte colony-stimulating factor support, with different chemotherapy models favoring the maximally escalated bi- or tri-weekly regimen, respectively. Because a higher total dose can be achieved with six cycles of the tri-weekly compared with the biweekly regimen, CHOEP-21 at dose escalation level 3 was chosen for a nationwide randomized comparison with baseline CHOEP-21 in a subsequent phase III trial."],["dc.identifier.doi","10.1093/annonc/mdm497"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6328"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60319"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]